Marilia Amavel Gomes Soares

Dr. Marilia Amavel Gomes Soares

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
MSMarilia Amavel Gomes Soares
Marilia Amavel Gomes Soares
PAPaloma Anorita de Aquino
Paloma Anorita de Aquino
TCTelma Costa
Telma Costa
CSCarlos Serpa
Carlos Serpa
OCOtávio Chaves
Otávio Chaves

7 June 2024 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
MSMarilia Amavel Gomes Soares
Marilia Amavel Gomes Soares
FSFranklin Souza Silva
Franklin Souza Silva
Carlos Roberto AlvesCarlos Roberto Alves
Carlos Roberto Alves
LVLeonardo Vazquez
Leonardo Vazquez
TATalita Stelling de Araujo
Talita Stelling de Araujo
OCOtávio Chaves
Otávio Chaves
Cardiovascular diseases (CVDs), especially arterial hypertension, stand as prominent contributors to global mortality. Regrettably, individuals with diabetes encounter a two-fold increase in the risk of mortality associated with CVDs. Hydrochlorothiazide (HCTZ) represents a primary intervention for hypertension, particularly in diabetic patients. Nevertheless, there has not yet been a comprehensive assessment of the biophysical characteristics regarding the impact of glucose levels on its binding affinity with human serum albumin (HSA). Thus, the present work reports the interactive profile of HSA/HCTZ in nonglycemic, normoglycemic (80 mg/dL), and hyperglycemic (320 mg/dL) conditions by time-resolved fluorescence, saturation transfer difference–nuclear magnetic resonance (STD-NMR), and surface plasmon resonance (SPR). There was a moderate ground state association of HSA/HCTZ with subdomain IIA that was affected in the presence of different glucose levels. The hyperglycemic condition decreased the binding affinity of HCTZ to subdomain IIA and increased the possibility of subdomain IB also being considered as a secondary binding site due to cooperativity and/or alterations in the protein’s structure. Overall, the glucose level under hyperglycemic conditions led to the cavities being more likely to receive more ligands, offering insights into the necessity of glucose control in the human bloodstream to not impact the residence time (pharmacokinetic profile) and pharmacotherapeutic potential of HCTZ.

15 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NGNatália Gomes-da-Silva
Natália Gomes-da-Silva
IXIsabelle Xavier-de-Britto
Isabelle Xavier-de-Britto
MSMarilia Amavel Gomes Soares
Marilia Amavel Gomes Soares
NYNatalia Yoshihara
Natalia Yoshihara
DİDerya İlem-Özdemir
Derya İlem-Özdemir
RSRalph Santos-Oliveira
Ralph Santos-Oliveira
Background/Objectives: Lipoxins, particularly Lipoxin A4 (LXA4), are endogenous lipid mediators with potent anti-inflammatory and pro-resolving properties, making them promising candidates for the treatment of inflammatory and neurodegenerative disorders. However, their therapeutic application is limited by poor stability and bioavailability. This study aimed to develop and characterize nanomicelles encapsulating LXA4 (nano-lipoxin A4) to improve its pharmacological efficacy against Alzheimer’s disease (AD), a neurodegenerative condition marked by chronic inflammation and beta-amyloid (Aβ) accumulation. Methods: Nano-lipoxin A4 was synthesized using Pluronic F-127 as a carrier and characterized in terms of morphology, physicochemical stability, and in vitro activity against Aβ fibrils. Dissociation of Aβ fibrils was assessed via Thioflavin-T fluorescence assays and transmission electron microscopy. In vivo biodistribution and pharmacokinetic profiles were evaluated using technetium-99m-labeled nano-lipoxin A4 in rodent models. Hepatic biochemical parameters were also measured to assess potential systemic effects. Results: In vitro studies demonstrated that nano-lipoxin A4 effectively dissociated Aβ fibrils at concentrations of 50 nM and 112 nM. Electron microscopy confirmed the disruption of fibrillar structures. In vivo imaging revealed predominant accumulation in the liver and spleen, consistent with reticuloendothelial system uptake. Pharmacokinetic analysis showed a prolonged half-life (63.95 h) and low clearance rate (0.001509 L/h), indicating sustained systemic presence. Biochemical assays revealed elevated liver enzyme levels, suggestive of increased hepatic metabolism or potential hepatotoxicity. Conclusions: Nano-lipoxin A4 exhibits significant therapeutic potential for Alzheimer’s disease through effective modulation of Aβ pathology and favorable pharmacokinetic characteristics. However, the elevation in liver enzymes necessitates further investigation into systemic safety to support clinical translation.

Verified
Journal Article
Open access
PDF file
VFViviane Fragoso
Viviane Fragoso
CCCarla Patrícia De Morais Coura
Carla Patrícia De Morais Coura
LHLuanda Yanaan Hoppe
Luanda Yanaan Hoppe
MSMarilia Amavel Gomes Soares
Marilia Amavel Gomes Soares
DSDilson Silva
Dilson Silva
CCCelia Martins Cortez
Celia Martins Cortez
The aim of this work was to study the interaction of sulpiride with human serum albumin (HSA) and bovine serum albumin (BSA) through the fluorescence quenching technique. As sulpiride molecules emit fluorescence, we have developed a simple mathematical model to discriminate the quencher fluorescence from the albumin fluorescence in the solution where they interact. Sulpiride is an antipsychotic used in the treatment of several psychiatric disorders. We selectively excited the fluorescence of tryptophan residues with 290 nm wavelength and observed the quenching by titrating HSA and BSA solutions with sulpiride. Stern-Volmer graphs were plotted and quenching constants were estimated. Results showed that sulpiride form complexes with both albumins. Estimated association constants for the interaction sulpiride–HSA were 2.20 (±0.08) × 104 M−1, at 37 °C, and 5.46 (±0.20) × 104 M−1, at 25 °C. Those for the interaction sulpiride-BSA are 0.44 (±0.01) × 104 M−1, at 37 °C and 2.17 (±0.04) × 104 M−1, at 25 °C. The quenching intensity of BSA, which contains two tryptophan residues in the peptide chain, was found to be higher than that of HSA, what suggests that the primary binding site for sulpiride in albumin should be located next to the sub domain IB of the protein structure.

29 September 2016 in Physica B: Condensed Matter
Verified
Journal Article
Closed access
PDF file
MSMarilia Amavel Gomes Soares
Marilia Amavel Gomes Soares
CCCelia Martins Cortez
Celia Martins Cortez
FCFrederico Alan de Oliveira Cruz
Frederico Alan de Oliveira Cruz
DSDilson Silva
Dilson Silva

1 January 2015 in AIP Conference Proceedings
Verified
Conference Paper
Closed access
MSMarilia Amavel Gomes Soares
Marilia Amavel Gomes Soares
FCFrederico A. O. Cruz
Frederico A. O. Cruz
DSDilson Silva
Dilson Silva
We determined the magnetic field around sodium and potassium ionic channels based on a physico-mathematical model that took into account charges in the surface bilayer. For the numerical simulation, we applied the finite element method. Results show that each channel produces its specific and individual response to the ion transport, according to its individual intrinsic properties. The existence of a number of active Na +-channels in a given membrane region seems not to interfere directly in the functioning of K+-channel located among them, and vice-versa.